TRKA, Active Human Recombinant Protein
- Known as:
- TRKA, Active Human Recombinant Protein
- Catalog number:
- 40280
- Product Quantity:
- 10 µg
- Category:
- -
- Supplier:
- Biotech support group
- Gene target:
- TRKA Active Human Recombinant Protein
Related genes to: TRKA, Active Human Recombinant Protein
- Gene:
- NTRK1 NIH gene
- Name:
- neurotrophic receptor tyrosine kinase 1
- Previous symbol:
- -
- Synonyms:
- TRK, TRKA, MTC
- Chromosome:
- 1q23.1
- Locus Type:
- gene with protein product
- Date approved:
- 1991-07-18
- Date modifiied:
- 2019-04-23
Related products to: TRKA, Active Human Recombinant Protein
Related articles to: TRKA, Active Human Recombinant Protein
- , , and gene fusions are rare oncogenic driver alterations found in diverse tumor types of adults and children. They are clinically important biomarkers as tumors harboring these genomic alterations have high response rates to targeted therapy. Routine testing for fusions and treatment with TRK inhibitors has been recommended in multiple tumor types; however, differences between testing technologies used for detecting fusions can result in variable likelihoods of identification. - Source: PubMed
Publication date: 2025/05/02
Wallen Zachary DTierno MarniSchnettler EricaRoos AlisonGreen MichelleAmoah KobinaPrevis Rebecca AHastings StephaniePabla SarabjotJensen Taylor JCaveney BrianEisenberg MarciaSathyan PratheeshRamkissoon Shakti HSeverson Eric A - Thiol-containing drugs may interact with a region of tropomyosin receptor kinase A (TrkA), potentially inhibiting its activation by nerve growth factor (NGF). This action has been linked to potential analgesic activities. Here, we describe the ability of erdosteine, a thiolic compound classified as a mucolytic agent, to bind to the TrkA receptor sequence in silico and its in vitro effects on TrkA activation induced by NGF in cultured human neuroblastoma cells. Our results show that erdosteine and its metabolite, Met-1, bind to the TrkA receptor pocket, involving the primary TrkA residues Glu331, Arg347, His298, and His297. Furthermore, Met-1 has the ability to reduce the disulfide bridge between Cys300 and Cys345 of TrkA. In vitro measurement of TrkA autophosphorylation following NGF activation confirmed that erdosteine and Met-1 interfere with NGF-induced TrkA activation, leading to a consequent loss of the molecular recognition and spatial reorganization necessary for the induction of the autophosphorylation process. This effect was inhibited by low millimolar concentrations of the two compounds, reaching a maximal inhibition (around 40%) after 24 h of exposure to 1 mM erdosteine, and then plateauing. These findings suggest that erdosteine can act as a TrkA antagonist, thus indicating that this drug may have potential as an analgesic via a novel non-opioid mechanism of action operating through NGF signaling inhibition at the level of TrkA. - Source: PubMed
Publication date: 2025/04/25
Marchesi NicolettaGovoni StefanoPage Clive PDiatchenko LudaPascale AlessiaFantucci PiercarloVertemara JacopoNatoli SilviaAllegri Massimo - Gene fusions are an important driver of cancer and require rapid and accurate detection to guide clinical decisions. However, the performance characteristics of whole transcriptome sequencing (WTS) for the detection of gene fusions have not been thoroughly investigated. - Source: PubMed
Publication date: 2025/05/08
Zhao SongchenDu XinhuaZhang YanBai JingMeng LuLi XuefeiMa JiaxinSheng HeYuFu XiaoruiGuan YanfangYi YutingYang LingXia XuefengYi XinTan XinxinZhou Caicun - Lung cancer is the leading cause of cancer deaths globally, with 1.8 million deaths annually. Advances in targeted therapy and molecular testing for key mutations in non-small cell lung cancer (NSCLC) have improved survival rates. The benchmark turnaround time for molecular testing is 10 days; however, send-out next-generation sequencing (NGS) can often take 14 to 28 days. - Source: PubMed
Publication date: 2025/05/07
Hogarth Nathan CAl-Kawaaz MustafaLinder Mark W - Gastrointestinal malignancies account for 25% of all cancer cases and 35% of cancer-related mortality. Next-generation sequencing (NGS) can elucidate the genomic landscape of gastrointestinal cancers; tissue-based genotyping has traditionally been used, but liquid biopsy-based genotyping is a non-invasive alternative. Moreover, geographical variations in the genomic landscape of gastrointestinal cancers have not been fully elucidated. This retrospective study aimed to gain insight into the genomic landscape of patients with gastrointestinal cancers from the Asia and Middle East (AME) region using plasma-derived circulating tumor DNA (ctDNA). - Source: PubMed
Publication date: 2025/05/05
Muto ManabuSunakawa YuSandhir NippunLiang Yi HsinDawood ShaheenahRohatgi NiteshBahl AnkurOlsen Steve